Showing 2,941 - 2,960 results of 113,842 for search '(( 5 ((mean decrease) OR (a decrease)) ) OR ( 50 ((mean decrease) OR (a decrease)) ))', query time: 1.72s Refine Results
  1. 2941
  2. 2942
  3. 2943
  4. 2944
  5. 2945
  6. 2946
  7. 2947
  8. 2948
  9. 2949
  10. 2950

    Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total levels and phosphorylation of Bcr-Abl, a decrease of downstream phosphorylated STAT5 and a caspase-dependent cell death in TKIs-resistant and –sensitive K562 cell lines. by Octavian Bucur (470431)

    Published 2013
    “…K562 and K562-R cells were treated with 9nM bortezomib and 8nM BI 2536 for 60h, followed by the detection of Bcr-Abl and phosphorylated STAT5. The combined treatment resulted in a marked decrease of the total levels of Bcr-Abl, which correlates with a decrease in the phosphorylation of the downstream STAT5 protein, in both K562 and K562-R cells. β-Actin was used as an internal loading control. …”
  11. 2951
  12. 2952
  13. 2953
  14. 2954

    Image2_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF by Boao Xie (11621803)

    Published 2021
    “…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
  15. 2955

    Image1_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF by Boao Xie (11621803)

    Published 2021
    “…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
  16. 2956
  17. 2957
  18. 2958
  19. 2959

    Effect on the metabolic clearance rate (MCR) of CK under the inhibition of recombinant CYP2C9 and CYP3A4. by Jian Xiao (253329)

    Published 2016
    “…The MCRs of CK were significantly decreased compared with those of the control for CYP3A4 and CYP2C9.…”
  20. 2960